[A comparison of the quality of life of prostatic cancer patients under slow releasing LH-RH analogue (TAP-144SR Depot) treatment or synthetic estrogen treatment].
The quality of life (QOL) was studied on 31 prostatic cancer (PC) patients, being followed at our out-patient-clinic during a relapse-free period. Fifteen of them were under treatment with a slow releasing LH-RH analogue (TAP-144 SR Depot) (TAP) and the other 16 prostatic cancer patients with synthetic estrogen (Honvan) (DES). The QOL of 37 benign prostatic hyperplasia (BPH) patients on conservative treatment was also studied. Concerning their general feeling of health, the prostatic cancer patients on TAP treatment felt subjectively better than those on DES. The social life of the patients on TAP or those who had BPH was less affected than that of those on DES. The quality of sexual life was worse for the prostatic cancer patients on both TAP and DES treatment than for the BPH patients.
Oishi
K
K
Department of Urology, Faculty of Medicine, Kyoto University.
Arai
Y
Y
Takeuchi
H
H
Yoshida
O
O
D000368:Aged; D000369:Aged, 80 and over; D003692:Delayed-Action Preparations; D004054:Diethylstilbestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000523:psychology / Q000534:rehabilitation; D011788:Quality of Life; D012725:Sexual Behavior; D011795:Surveys and Questionnaires
D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol; C004955:fosfestrol